Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness of Olaparib and Bevacizumab for Maintenance Treatment in Patients with HRD-Positive Ovarian Cancer

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effectiveness of a treatment for patients with advanced, high-grade epithelial ovarian cancer, including cancer of the fallopian tube or primary peritoneal cancer. The study involves patients whose tumors show a specific genetic defect in a DNA repair mechanism known as homologous recombination deficiency (HRD). The treatment being tested combines two medications: olaparib, which is a type of drug known as a PARP inhibitor, and bevacizumab, a monoclonal antibody. These medications are given as maintenance therapy, which means they are used to help keep the cancer from coming back after the initial treatment.

The purpose of the study is to confirm how well this combination works in patients who have already received a standard chemotherapy treatment that includes a platinum-based drug and bevacizumab. After completing this initial treatment, patients who show a complete or partial response and have HRD-positive tumors will start taking olaparib along with bevacizumab. The study will observe how patients respond to this maintenance therapy over time.

Participants in the trial will receive the treatment over a period of time, and their health will be monitored to see how the cancer responds and to check for any side effects. The study aims to provide more information about the effectiveness and safety of using olaparib and bevacizumab together in treating this type of cancer. The trial will also gather data on the characteristics of patients who benefit from this treatment approach.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the trial

    Upon joining the trial, informed consent is required. This means agreeing to participate after understanding the trial's purpose and procedures.

    Eligibility is confirmed based on specific criteria, including age, diagnosis of high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer, and other health conditions.

  2. Step 2

    Initial treatment

    The initial treatment involves a combination of chemotherapy and a medication called bevacizumab. This phase is designed to address the cancer directly.

    Chemotherapy is administered in cycles, and the specific schedule will be provided by the healthcare team.

  3. Step 3

    Maintenance therapy

    If the initial treatment is successful, maintenance therapy begins. This involves taking olaparib in combination with bevacizumab.

    Olaparib is taken orally in the form of tablets. The dosage is either 150 mg or 100 mg, as prescribed by the healthcare provider.

    The frequency and duration of taking olaparib will be determined by the healthcare team based on individual response and tolerance.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring is conducted to assess the effectiveness of the treatment and to check for any side effects.

    Follow-up appointments will be scheduled to evaluate progress and make any necessary adjustments to the treatment plan.

  5. Step 5

    Completion of trial

    The trial is expected to continue until June 2026, but individual participation may vary based on personal health and response to treatment.

    Upon completion, final assessments will be conducted to gather data on the treatment's efficacy and safety.

Who can join the trial?

10 criteria

  • Provide informed consent, which means you agree to participate after understanding the study details.
  • You must be at least 18 years old.
  • Have a new diagnosis of high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer.
  • Have advanced disease, classified as FIGO stage III-IV. FIGO is a system used to describe the extent of cancer.
  • Provide tumor samples from your primary cancer for testing. These samples must be preserved in a specific way called formalin-fixed, paraffin-embedded (FFPE).
  • Be suitable to receive a specific type of chemotherapy called platinum-taxane chemotherapy along with a drug named bevacizumab.
  • Have normal organ and bone marrow function before starting the chemotherapy and bevacizumab treatment.
  • Have normal blood pressure or controlled high blood pressure, with systolic blood pressure ≤ 140 mmHg and/or diastolic blood pressure ≤ 90 mmHg.
  • Have an ECOG performance status of 0-1, which means you are fully active or have some symptoms but can carry out light work.
  • Have a life expectancy of at least 16 weeks.

Who cannot join the trial?

6 criteria

  • Patients who do not have a confirmed diagnosis of advanced, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • Patients who are not eligible to start a chemotherapy regimen with the drug bevacizumab. Bevacizumab is a medication used to treat certain types of cancer by slowing the growth of new blood vessels that tumors need to grow.
  • Patients whose tumor samples do not show a positive result for HRD status using the Myriad Mychoice CDxPlus test. HRD status refers to a condition where the tumor has a deficiency in repairing DNA damage, which can make it more responsive to certain treatments.
  • Patients who do not achieve a complete or partial response after initial treatment with platinum-based chemotherapy plus bevacizumab. A complete response means no signs of cancer are found, while a partial response means the cancer has shrunk but is still present.
  • Patients who do not have a tumor with a BRCA1-2 mutation as determined by the Myriad Mychoice CDx Plus evaluation. BRCA1-2 mutations are changes in specific genes that can increase the risk of certain cancers.
  • Patients who do not meet other specific eligibility criteria for starting treatment with olaparib in addition to bevacizumab. Olaparib is a medication used to treat certain types of cancer by interfering with the cancer cells' ability to repair their DNA.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Olaparib

    is a medication used in this trial to help treat ovarian cancer. It works by blocking a specific protein in cancer cells, which helps to stop the cancer from growing and spreading. In this study, olaparib is used as a maintenance treatment, which means it is given to help keep the cancer from coming back after the initial treatment.

  • Bevacizumab

    is another medication used in this trial alongside olaparib. It works by targeting and blocking a protein that helps cancer cells form new blood vessels. By doing this, bevacizumab helps to cut off the blood supply that the cancer needs to grow. In this study, it is used as part of the maintenance treatment to help prevent the cancer from returning after the first round of chemotherapy.

What is already known about the treatment

  • Olaparib

    Olaparib is taken orally and is used as a maintenance treatment for patients with certain types of ovarian cancer. It is currently recognized in medical literature as an effective therapy for patients with HRD-positive tumors, including those with BRCA1-2 mutations, who have responded to initial chemotherapy. Olaparib works by inhibiting a protein called PARP, which helps repair damaged DNA in cells. By blocking PARP, olaparib prevents cancer cells from repairing themselves, leading to their death. It is classified as a PARP inhibitor in pharmacology.

  • Bevacizumab

    Bevacizumab is administered through an intravenous infusion and is used in combination with chemotherapy for treating advanced ovarian cancer. It is well-established in medical practice as a therapy that helps improve outcomes for patients with this type of cancer. Bevacizumab works by blocking a protein called VEGF, which is responsible for the growth of new blood vessels that tumors need to grow. By inhibiting VEGF, bevacizumab reduces the blood supply to the tumor, slowing its growth. It is classified as an angiogenesis inhibitor in pharmacology.

Investigated diseases

  • Epithelial Ovarian Cancer

    Epithelial ovarian cancer is a type of cancer that begins in the layer of cells covering the ovaries. It is characterized by the abnormal growth of cells that can invade or spread to other parts of the body. The disease often progresses silently, with symptoms appearing only in advanced stages. As it advances, it may cause abdominal swelling, pain, and changes in bowel habits. The cancer can spread to the lining of the abdomen and other organs. It is often detected at a later stage due to its subtle early symptoms.

  • Fallopian Tube Cancer

    Fallopian tube cancer is a rare type of cancer that originates in the fallopian tubes, which connect the ovaries to the uterus. It typically begins in the cells lining the inside of the tubes. The disease progresses as the cancerous cells grow and potentially spread to nearby organs and tissues. Symptoms may include pelvic pain, abnormal vaginal discharge, and a palpable mass. As the cancer advances, it can affect the surrounding reproductive organs and the abdominal cavity. Early detection is challenging due to the non-specific nature of initial symptoms.

  • Primary Peritoneal Cancer

    Primary peritoneal cancer is a rare cancer that starts in the peritoneum, the thin layer of tissue lining the abdomen. It is similar to epithelial ovarian cancer in terms of its behavior and progression. The disease progresses as cancer cells grow and spread within the abdominal cavity. Symptoms may include abdominal pain, bloating, and changes in bowel habits. As it advances, it can affect the function of abdominal organs and lead to fluid accumulation. The cancer is often diagnosed at an advanced stage due to its subtle early symptoms.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-502242-27-00Protocol codeIRFMN-OVA-8542Estimated enrolment190 patientsSponsorIstituto Di Ricerche Farmacologiche Mario Negri

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).